We are ready for clinical implementation of Carbon Ion Radiotherapy in the United States

Beltran, Chris; Amos, R.; Rong, Yi

doi:10.1002/acm2.13133

Cited by 10 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both sides of the CIRT debate emphasise the need for high-level evidence generation. 127,128 However, this needs a sufficient number of CIRT centres, clear intertransferability of approaches and strong collaborative network and trials infrastructures. 129,130 Australia is well placed to contribute to international studies and also to lead studies within the robust TROG (Trans-Tasman Radiation Oncology Group) framework for radiation oncology clinical trials.…”

Section: Clinical Trialsmentioning

confidence: 99%

See 1 more Smart Citation

The rationale for a carbon ion radiation therapy facility in Australia

Thwaites,

Prokopovich,

Garrett

et al. 2023

J of Medical Radiation Sci

View full text Add to dashboard Cite

Australia has taken a collaborative nationally networked approach to achieve particle therapy capability. This supports the under‐construction proton therapy facility in Adelaide, other potential proton centres and an under‐evaluation proposal for a hybrid carbon ion and proton centre in western Sydney. A wide‐ranging overview is presented of the rationale for carbon ion radiation therapy, applying observations to the case for an Australian facility and to the clinical and research potential from such a national centre.

show abstract

Section: Clinical Trialsmentioning

confidence: 99%

“…Both sides of the CIRT debate emphasise the need for high‐level evidence generation 127,128 . However, this needs a sufficient number of CIRT centres, clear inter‐transferability of approaches and strong collaborative network and trials infrastructures 129,130 .…”

Section: Clinical Applications and Experience Of Cirtmentioning

confidence: 99%

The rationale for a carbon ion radiation therapy facility in Australia

Thwaites,

Prokopovich,

Garrett

et al. 2023

J of Medical Radiation Sci

View full text Add to dashboard Cite

show abstract

“…Mayo Clinic Florida (MCF) is currently building the first proton-carbon therapy center in the United States of America (Beltran et al 2020). In order to overcome some limitations of previous MKMs (Parisi et al 2022d), we recently developed and benchmarked an alternative implementation of the MKM, named MCF MKM (Parisi et al 2022a(Parisi et al , 2022b.…”

Section: Introductionmentioning

confidence: 99%

Variable RBE in proton radiotherapy: a comparative study with the predictive Mayo Clinic Florida microdosimetric kinetic model and phenomenological models of cell survival

Parisi,

Beltran,

Furutani

2023

Phys. Med. Biol.

View full text Add to dashboard Cite

Objectives. (1) To examine to what extent the cell- and exposure- specific information neglected in the phenomenological proton relative biological effectiveness (RBE) models could influence the computed RBE in proton therapy. (2) To explore similarities and differences in the formalism and the results between the linear energy transfer (LET)-based phenomenological proton RBE models and the microdosimetry-based Mayo Clinic Florida microdosimetric kinetic model (MCF MKM). (3) To investigate how the relationship between the RBE and the dose-mean proton LET is affected by the proton energy spectrum and the secondary fragments. Approach. We systematically compared six selected phenomenological proton RBE models with the MCF MKM in track-segment simulations, monoenergetic proton beams in a water phantom, and two spread-out Bragg peaks. A representative comparison with in vitro data for human glioblastoma cells (U87 cell line) is also included. Main results. Marked differences were observed between the results of the phenomenological proton RBE models, as reported in previous studies. The dispersion of these models’ results was found to be comparable to the spread in the MCF MKM results obtained by varying the cell-specific parameters neglected in the phenomenological models. Furthermore, while single cell-specific correlation between RBE and the dose-mean proton LET seems reasonable above 2 keV μm−1, caution is necessary at lower LET values due to the relevant contribution of secondary fragments. The comparison with in vitro data demonstrates comparable agreement between the MCF MKM predictions and the results of the phenomenological models. Significance. The study highlights the importance of considering cell-specific characteristics and detailed radiation quality information for accurate RBE calculations in proton therapy. Furthermore, these results provide confidence in the use of the MCF MKM for clonogenic survival RBE calculations in proton therapy, offering a more mechanistic approach compared to phenomenological models.

show abstract

“…In view of the upcoming integrated proton-carbon ion therapy center at Mayo Clinic Florida (MCF, Jacksonville, Florida, United States of America [ 32 ]), a novel microdosimetric model named MCF MKM was recently developed [ 33 ]. Differently from previous versions of the MKM [ 5 , 8 , 9 ], the MCF MKM introduces novel expressions to calculate the exposure-specific values of α and ß by using whole spectral information.…”

Section: Introductionmentioning

confidence: 99%

The Mayo Clinic Florida Microdosimetric Kinetic Model of Clonogenic Survival: Application to Various Repair-Competent Rodent and Human Cell Lines

Parisi

Beltran

Furutani

2022

IJMS

View full text Add to dashboard Cite

The relative biological effectiveness (RBE) calculations used during the planning of ion therapy treatments are generally based on the microdosimetric kinetic model (MKM) and the local effect model (LEM). The Mayo Clinic Florida MKM (MCF MKM) was recently developed to overcome the limitations of previous MKMs in reproducing the biological data and to eliminate the need for ion-exposed in vitro data as input for the model calculations. Since we are considering to implement the MCF MKM in clinic, this article presents (a) an extensive benchmark of the MCF MKM predictions against corresponding in vitro clonogenic survival data for 4 rodent and 10 cell lines exposed to ions from 1H to 238U, and (b) a systematic comparison with published results of the latest version of the LEM (LEM IV). Additionally, we introduce a novel approach to derive an approximate value of the MCF MKM model parameters by knowing only the animal species and the mean number of chromosomes. The overall good agreement between MCF MKM predictions and in vitro data suggests the MCF MKM can be reliably used for the RBE calculations. In most cases, a reasonable agreement was found between the MCF MKM and the LEM IV.

show abstract

We are ready for clinical implementation of Carbon Ion Radiotherapy in the United States

Cited by 10 publications

References 15 publications

The rationale for a carbon ion radiation therapy facility in Australia

The rationale for a carbon ion radiation therapy facility in Australia

Variable RBE in proton radiotherapy: a comparative study with the predictive Mayo Clinic Florida microdosimetric kinetic model and phenomenological models of cell survival

The Mayo Clinic Florida Microdosimetric Kinetic Model of Clonogenic Survival: Application to Various Repair-Competent Rodent and Human Cell Lines

Contact Info

Product

Resources

About